Investing.com -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ)公布的第二季度业绩未能达到分析师预期,尽管收入略微超出预估,但股价仍下跌2%。 这家生物制药公司第二季度调整后亏损每股8.25美元,低于分析师预期的每股亏损7.62美元。收入为10.5亿美元,略高于市场一致预期的10.4亿美元,同比增长2.1%。财报发布后,该公司股价下跌2%,主要原因...
Source LinkInvesting.com -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ)公布的第二季度业绩未能达到分析师预期,尽管收入略微超出预估,但股价仍下跌2%。 这家生物制药公司第二季度调整后亏损每股8.25美元,低于分析师预期的每股亏损7.62美元。收入为10.5亿美元,略高于市场一致预期的10.4亿美元,同比增长2.1%。财报发布后,该公司股价下跌2%,主要原因...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.